On September 24, Hims & Hers Health Inc. declined 5.09% in regular trading, trading at $28.85/share with turnover of $146 million, reversing sharply after two consecutive sessions of gains exceeding 5%.

The pullback comes as multiple Form 144 filings for proposed securities sales were submitted by company insiders in recent weeks, signaling potential selling pressure. Meanwhile, the company recently announced the removal of its $49 generic weight-loss drug from its platform, a product category that had been a key growth driver but also a source of regulatory and operational friction, including enrollment in Visa's Acquirer Monitoring Program due to excessive credit card disputes in its weight-loss subscription business.

The broader healthcare services sector also traded weaker, with Labcorp Holdings down 1.72%, CVS Health down 1.37%, Cigna Group down 1.31%, Guardant Health down 0.42%, and Quest Diagnostics down 0.22%. The company continues to navigate headwinds from an FTC lawsuit alleging improper user data sharing, while Q2 results in August showed a wider-than-expected loss of $0.37 per share despite 38% revenue growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)